Historical Stock Price
ABEO historical stock prices picture
Abeona Therapeutics (ABEO) has the following price history information. Looking back at ABEO historical stock prices for the last five trading days, on October 17, 2019, ABEO opened at $2.39, traded as high as $2.50 and as low as $2.21, and closed at $2.26. Trading volume was a total of 724.20K shares. On October 18, 2019, ABEO opened at $2.22, traded as high as $2.39 and as low as $2.11, and closed at $2.17. Trading volume was a total of 584.70K shares. On October 21, 2019, ABEO opened at $2.16, traded as high as $2.30 and as low as $2.12, and closed at $2.26. Trading volume was a total of 385.30K shares. On October 22, 2019, ABEO opened at $2.27, traded as high as $2.45 and as low as $2.27, and closed at $2.39. Trading volume was a total of 373.10K shares. On October 23, 2019, ABEO opened at $2.39, traded as high as $2.50 and as low as $2.30, and closed at $2.39. Trading volume was a total of 274.20K shares.

ABEO Historical Stock Prices By Date:

ABEO historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into Abeona Therapeutics shares, starting with a $10,000 purchase of ABEO, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 10/23/2009
End date: 10/23/2019
Start price/share: $3.35
End price/share: $2.39
Dividends collected/share: $0.00
Total return: -28.66%
Average Annual Total Return: -3.32%
Starting investment: $10,000.00
Ending investment: $7,133.23
Years: 10.01
Date Open High Low Close Volume
10/17/2019 $2.39 $2.50 $2.21 $2.26 724.20K
10/18/2019 $2.22 $2.39 $2.11 $2.17 584.70K
10/21/2019 $2.16 $2.30 $2.12 $2.26 385.30K
10/22/2019 $2.27 $2.45 $2.27 $2.39 373.10K
10/23/2019 $2.39 $2.50 $2.30 $2.39 274.20K
Abeona Therapeutics is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Co.'s main programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A, and ABO-101 an AAV-based gene therapy for Sanfilippo syndrome type B. Co. is also developing ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten Disease, respectively, ABO-401 for the treatment of cystic fibrosis, and ABO-5OX for the treatment of retinal diseases.
Date Close
10/17/2019$2.26
10/18/2019$2.17
10/21/2019$2.26
10/22/2019$2.39
10/23/2019$2.39
ABEO is categorized under the Healthcare sector; below are some other companies in the same sector:

ABIO Historical Stock Prices
ABMD Historical Stock Prices
ABT Historical Stock Prices
ABV Historical Stock Prices
ACAD Historical Stock Prices
ACER Historical Stock Prices
ACET Historical Stock Prices
ACHC Historical Stock Prices
ACHN Historical Stock Prices
ACHV Historical Stock Prices

Also explore: ABEO shares outstanding history


ABEO Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2019, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.